Literature DB >> 20878952

TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients.

Cristina Magi-Galluzzi1, Toyonori Tsusuki, Paul Elson, Kelly Simmerman, Chris LaFargue, Raquel Esgueva, Eric Klein, Mark A Rubin, Ming Zhou.   

Abstract

BACKGROUND: Prostate cancer (PCa) exhibits significant differences in prevalence and mortality among different ethnic groups. The underlying genetics is not well understood. TMPRSS2-ERG fusion is a common recurrent chromosomal aberration in PCa and is however not studied among different ethnic groups. We examined the prevalence and class of TMPRSS2-ERG gene fusion in PCa from Caucasian, African-American, and Japanese patients.
MATERIALS AND METHODS: A tissue microarray of PCa from 42 Caucasians, 64 African-Americans, and 44 Japanese patients who underwent radical prostatectomies (RP) was studied for TMPRSS2-ERG fusion using a multicolor interphase fluorescence in situ hybridization assay for ERG gene break-apart.
RESULTS: TMPRSS2-ERG gene fusion was present in 50% (21/42) of Caucasians, 31.3% (20/64) of African-Americans, and 15.9% (7/44) of Japanese (P=0.003). The gene fusion through translocation, deletion, or both occurred in 61.9% (13/21), 38.1% (8/21), and 0% (0/21) in Caucasians, 20% (4/20), 60% (12/20), and 20% (4/20) in African-Americans, and 71.4% (5/7), 28.6% (2/7), and 0% (0/7) in Japanese patients (P=0.02). A multivariate analysis demonstrated that TMPRSS2-ERG gene fusion correlated with the ethnicity (P=0.03), marginally correlated with the pathologic stage (P=0.06), but not other clinicopathologic parameters, including age, preoperative PSA levels, and Gleason score.
CONCLUSIONS: The prevalence and class of TMPRSS2-ERG are significantly different in PCa of Caucasian, African-American, and Japanese patients. Future studies of the molecular pathways implicated in TMPRSS2-ERG gene fusion may shed light on the disparity in prevalence and mortality of PCa among different ethnic groups and help design better prevention and treatment strategies.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20878952     DOI: 10.1002/pros.21265

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  125 in total

1.  Insights into Chinese prostate cancer with RNA-seq.

Authors:  Anirban Sahu; Matthew K Iyer; Arul M Chinnaiyan
Journal:  Cell Res       Date:  2012-03-27       Impact factor: 25.617

Review 2.  TMPRSS2:ERG Gene Fusions in Prostate Cancer of West African Men and a Meta-Analysis of Racial Differences.

Authors:  Cindy Ke Zhou; Denise Young; Edward D Yeboah; Sally B Coburn; Yao Tettey; Richard B Biritwum; Andrew A Adjei; Evelyn Tay; Shelley Niwa; Ann Truelove; Judith Welsh; James E Mensah; Robert N Hoover; Isabell A Sesterhenn; Ann W Hsing; Shiv Srivastava; Michael B Cook
Journal:  Am J Epidemiol       Date:  2017-12-15       Impact factor: 4.897

Review 3.  Addressing the need for repeat prostate biopsy: new technology and approaches.

Authors:  Michael L Blute; E Jason Abel; Tracy M Downs; Frederick Kelcz; David F Jarrard
Journal:  Nat Rev Urol       Date:  2015-07-14       Impact factor: 14.432

4.  Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations.

Authors:  Franklin W Huang; Juan Miguel Mosquera; Andrea Garofalo; Coyin Oh; Maria Baco; Ali Amin-Mansour; Bokang Rabasha; Samira Bahl; Stephanie A Mullane; Brian D Robinson; Saud Aldubayan; Francesca Khani; Beerinder Karir; Eejung Kim; Jeremy Chimene-Weiss; Matan Hofree; Alessandro Romanel; Joseph R Osborne; Jong Wook Kim; Gissou Azabdaftari; Anna Woloszynska-Read; Karen Sfanos; Angelo M De Marzo; Francesca Demichelis; Stacey Gabriel; Eliezer M Van Allen; Jill Mesirov; Pablo Tamayo; Mark A Rubin; Isaac J Powell; Levi A Garraway
Journal:  Cancer Discov       Date:  2017-05-17       Impact factor: 39.397

5.  Calcium Channel Blocker Use and Risk of Prostate Cancer by TMPRSS2:ERG Gene Fusion Status.

Authors:  Milan S Geybels; Karen D McCloskey; Ian G Mills; Janet L Stanford
Journal:  Prostate       Date:  2016-10-18       Impact factor: 4.104

6.  MNX1 Is Oncogenically Upregulated in African-American Prostate Cancer.

Authors:  Li Zhang; Jianghua Wang; Yongquan Wang; Yiqun Zhang; Patricia Castro; Longjiang Shao; Arun Sreekumar; Nagireddy Putluri; Nilanjan Guha; Saligrama Deepak; Arunkumar Padmanaban; Chad J Creighton; Michael Ittmann
Journal:  Cancer Res       Date:  2016-08-30       Impact factor: 12.701

7.  Chinese and Western prostate cancers show alternate pathogenetic pathways in association with ERG status.

Authors:  Liyan Xue; Xueying Mao; Guoping Ren; Elzbieta Stankiewicz; Sakunthala C Kudahetti; Dongmei Lin; Luis Beltran; Daniel M Berney; Yong-Jie Lu
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

8.  Regulators of gene expression as biomarkers for prostate cancer.

Authors:  Stacey S Willard; Shahriar Koochekpour
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

9.  Overexpression of ETS-1 is associated with malignant biological features of prostate cancer.

Authors:  Bo Li; Yosuke Shimizu; Takashi Kobayashi; Naoki Terada; Koji Yoshimura; Tomomi Kamba; Yoshiki Mikami; Takahiro Inoue; Hiroyuki Nishiyama; Osamu Ogawa
Journal:  Asian J Androl       Date:  2012-10-15       Impact factor: 3.285

10.  A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.

Authors:  Thomas U Ahearn; Andreas Pettersson; Ericka M Ebot; Travis Gerke; Rebecca E Graff; Carlos L Morais; Jessica L Hicks; Kathryn M Wilson; Jennifer R Rider; Howard D Sesso; Michelangelo Fiorentino; Richard Flavin; Stephen Finn; Edward L Giovannucci; Massimo Loda; Meir J Stampfer; Angelo M De Marzo; Lorelei A Mucci; Tamara L Lotan
Journal:  J Natl Cancer Inst       Date:  2015-11-27       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.